These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
210 related items for PubMed ID: 21693290
1. Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation. Celik S, Doesch AO, Konstandin MH, Kristen AV, Ammon K, Sack FU, Schnabel P, Katus HA, Dengler TJ. Transplant Proc; 2011 Jun; 43(5):1862-7. PubMed ID: 21693290 [Abstract] [Full Text] [Related]
2. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK. J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681 [Abstract] [Full Text] [Related]
3. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS. Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429 [Abstract] [Full Text] [Related]
4. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster. Stypmann J, Engelen MA, Eckernkemper S, Amler S, Gunia S, Sindermann JR, Rothenburger M, Rukosujew A, Drees G, Welp HA. Transplant Proc; 2011 Jun 27; 43(5):1847-52. PubMed ID: 21693288 [Abstract] [Full Text] [Related]
9. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ. Transplantation; 2007 Mar 27; 83(6):722-6. PubMed ID: 17414704 [Abstract] [Full Text] [Related]
10. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients. Loar RW, Driscoll DJ, Kushwaha SS, Cramer CH, O'Leary PW, Daly RC, Mauriello DA, Johnson JN. Pediatr Transplant; 2013 Dec 27; 17(8):794-9. PubMed ID: 24164828 [Abstract] [Full Text] [Related]
12. Evolution of focal moderate (International Society for Heart and Lung Transplantation grade 2) rejection of the cardiac allograft. Milano A, Caforio AL, Livi U, Bauce B, Angelini A, Casarotto D, Thiene G. J Heart Lung Transplant; 1996 May 27; 15(5):456-60. PubMed ID: 8771500 [Abstract] [Full Text] [Related]
13. Early sirolimus therapy in renal transplant recipients at high risk: is it justified? Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR. Transplant Proc; 2009 Sep 27; 41(7):2784-8. PubMed ID: 19765435 [Abstract] [Full Text] [Related]
14. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. Costanzo MR, Koch DM, Fisher SG, Heroux AL, Kao WG, Johnson MR. J Heart Lung Transplant; 1997 Feb 27; 16(2):169-78. PubMed ID: 9059928 [Abstract] [Full Text] [Related]
20. Prognostic determinants of six-month morbidity and mortality in heart transplant recipients. The Italian Study Group on Infection in Heart Transplantation. De Maria R, Minoli L, Parolini M, Gavazzeni G, Gentile M, Grossi P, Livi U, Parisi F, Utili R. J Heart Lung Transplant; 1996 Feb 27; 15(2):124-35. PubMed ID: 8672515 [Abstract] [Full Text] [Related] Page: [Next] [New Search]